title: Effect of olprinone on liver microstructure in rat partial liver transplantation.
abstract: BACKGROUND
  Donor safety is a major concern in living-donor liver transplantation. However, partial grafts do not meet the functional demands of recipients and lead to small-for-size syndrome (SFSS). In a previous study, we showed that olprinone (OLP), a selective phosphodiesterase ІІІ inhibitor, up-regulates endothelial nitric oxide synthase level in the liver and attenuates shear stress, sinusoidal endothelial cell injury, and hepatocyte apoptosis after excessive liver resection in a rat model. We aimed to examine whether OLP treatment has beneficial effects on SFSS in a rat model of partial liver transplantation (PLT).
  
  
  METHODS
  We performed experiments in a rat model of 30% PLT. In the OLP group, we inserted an osmotic pump with OLP into the peritoneal cavity 48 h before liver graft sampling. Recipient rats were not treated with OLP. We examined the liver microstructure by electron microscopy and biochemical examination, and determined the 7-d survival of recipients.
  
  
  RESULTS
  In the OLP group 1 h after PLT, the sinusoidal endothelial cells of the liver were well preserved and we observed few vacuolar structures in hepatocytes. The total serum bilirubin level 1 wk after PLT tended to be lower in the OLP group than in the controls, and the liver microstructures were also well preserved in the OLP group. The probability of survival in the OLP group (100%; 14 of 14 rats) was significantly higher than that in the control group (75%; 15 of 20 rats).
  
  
  CONCLUSIONS
  Olprinone treatment was demonstrated to have therapeutic potential to overcome SFSS.
authors.affiliation: Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Kenya
authors.initials: K
authors.lastname: Yamanaka
authors.forename: Etsuro
authors.initials: E
authors.lastname: Hatano
authors.forename: Khota
authors.initials: K
authors.lastname: Iguchi
authors.forename: Gen
authors.initials: G
authors.lastname: Yamamoto
authors.forename: Motohiko
authors.initials: M
authors.lastname: Sato
authors.forename: Kan
authors.initials: K
authors.lastname: Toriguchi
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Tanabe
authors.forename: Kenji
authors.initials: K
authors.lastname: Takemoto
authors.forename: Kojiro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Koyama
authors.forename: Masato
authors.initials: M
authors.lastname: Narita
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Nagata
authors.forename: Kojiro
authors.initials: K
authors.lastname: Taura
authors.forename: Shinji
authors.initials: S
authors.lastname: Uemoto
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D042783:Endothelial Cells / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000648:ultrastructure; D017093:Liver Failure / Q000517:prevention & control*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D009929:Organ Size; D058987:Phosphodiesterase 3 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew
chemical_list: D007093:Imidazoles; D058987:Phosphodiesterase 3 Inhibitors; D011728:Pyridones; C059498:olprinone